AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 10 - (NewsRx.com & NewsRx.net) -- A recombinant Semliki Forest virus vector expressing human papillomavirus gene products appears to provide effective genetic immunization against cervical cancer in mice - even at relatively low doses.
Researchers in The Netherlands created a recombinant Semliki Forest virus (SFV) vector that expresses the human papillomavirus (HPV) proteins, E6 and E7. Expression of E6 and E7, they explained, is key to the transforming potential of HPV-16 and HPV-18, strains linked to development of cervical cancer via infection of genital epithelial cells.
"Since the expression of E6 and E7 is selectively maintained in premalignant and malignant cervical lesions, these proteins are attractive candidates for immunotherapeutic and prophylactic strategies," wrote T. Daemen and colleagues at the University of Groningen ("Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7," Gene Therapy, 2000;7(21):1859-1866).
The researchers demonstrated that SFV-delivered E6 and E7 proteins were, in fact, expressed in infected cells and reported that in mice, injection with SFV-E6E7 "resulted in an efficient in vivo priming of HPV-specific CTL [cytotoxic T lymphocyte] activity."
"The induced CTL ...
Source: HighBeam Research, Genetic Immunization Using Recombinant Alphavirus Vector of HPV...